{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:01:18Z","timestamp":1791896478873,"version":"4.3.4"},"reference-count":92,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant 82373843"],"award-info":[{"award-number":["Grant 82373843"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404584"],"award-info":[{"award-number":["82404584"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016067","name":"Shaanxi Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["Grant 2022\u2010SLRH\u2010YQ\u2010009, 2025\u2010ZY\u2010004"],"award-info":[{"award-number":["Grant 2022\u2010SLRH\u2010YQ\u2010009, 2025\u2010ZY\u2010004"]}],"id":[{"id":"10.13039\/100016067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016067","name":"Shaanxi Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2025\u2010CXTD\u201007"],"award-info":[{"award-number":["2025\u2010CXTD\u201007"]}],"id":[{"id":"10.13039\/100016067","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["chemistry-europe.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ChemMedChem"],"published-print":{"date-parts":[[2026,3,27]]},"abstract":"<jats:p>\n                    Vepdegestrant (ARV\u2010471) is an orally bioavailable, proteolysis\u2010targeting chimera (PROTAC)\u2010based estrogen receptor (ER) degrader and is among the most clinically advanced ER\u2010targeting PROTAC degraders, identified through a rational medicinal chemistry optimization campaign. It is being developed as an oral small\u2010molecule endocrine therapy for advanced or metastatic ER\u2010positive, human epidermal growth factor receptor 2 (HER2)\u2010negative breast cancer, with particular relevance for tumors harboring\n                    <jats:italic>ESR1<\/jats:italic>\n                    mutations. On June 6, 2025, Arvinas and Pfizer submitted a New Drug Application (NDA) for vepdegestrant to the U.S. Food and Drug Administration (FDA), representing an important step in the clinical translation of PROTAC technology. This review summarizes the design, synthesis, degradation mechanism, preclinical pharmacology, and clinical development of vepdegestrant and discusses the broader implications and future prospects of oral PROTAC\u2010based ER degraders in breast cancer therapy.\n                  <\/jats:p>","DOI":"10.1002\/cmdc.202501111","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T05:10:43Z","timestamp":1774242643000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Insights Into Vepdegestrant (ARV\u2010471): The First\u2010in\u2010Class Estrogen Receptor Proteolysis\u2010Targeting Chimera Approaching Food and Drug Administration Approval for Breast Cancer"],"prefix":"10.1002","volume":"21","author":[{"given":"Chao","family":"Tang","sequence":"first","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Tian","sequence":"additional","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxing","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Ke","sequence":"additional","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxin","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyan","family":"Wei","sequence":"additional","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintao","family":"Deng","sequence":"additional","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiannan","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhou","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xia","sequence":"additional","affiliation":[{"name":"Xixian New Area Fenghou Original Medical Technology Co.Ltd. Xixian Financial Port Energy and Financial Trade Zone  Xi\u2019an Shaanxi China"},{"name":"Zhanjiang Institute of Clinical Medicine Central People's Hospital of Zhanjiang Guangdong Medical University  Zhanjiang Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"He","sequence":"additional","affiliation":[{"name":"Xi\u2019an Taikomed Pharmaceutical Technology Co.Ltd.  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7360-8998","authenticated-orcid":false,"given":"Chengyuan","family":"Liang","sequence":"additional","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xixian New Area Fenghou Original Medical Technology Co.Ltd. Xixian Financial Port Energy and Financial Trade Zone  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9051-9468","authenticated-orcid":false,"given":"Lei","family":"Tian","sequence":"additional","affiliation":[{"name":"School of Biological and Pharmaceutical Sciences Shaanxi University of Science &amp; Technology Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xi\u2019an Key Laboratory for Antiviral and Antimicrobial\u2010Resistant Bacteria Therapeutics Research Weiyang University Park  Xi\u2019an Shaanxi China"},{"name":"Xixian New Area Fenghou Original Medical Technology Co.Ltd. Xixian Financial Port Energy and Financial Trade Zone  Xi\u2019an Shaanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization \u201cBreast Cancer \u201d (2025) accessed Oct 5 2025 https:\/\/www.who.int\/News\u2010Room\/Fact\u2010Sheets\/detail\/Breast\u2010Cancer."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.08.010"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20211033"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/or.2025.1564642"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2022.5184"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.01.040"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076834"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116393"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00523-4"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00424-y"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02483-8"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-052423-122001"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00443-1"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-2166"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251353623"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01137-5"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01401"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116184"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505725"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118055"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3465"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.11.031"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00966-4"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01818"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126630"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.4c00362"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01431-w"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2874"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13527"},{"key":"e_1_2_10_33_1","unstructured":"RCSB PDB Estrogen Receptor Alpha Ligand Binding Domain in Complex with Lasofoxifene:2020 accessed Oct 10 2025 https:\/\/www.rcsb.org\/structure\/6VJD."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202405939"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17040494"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00740"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000972"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02004-x"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2377530"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70401"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1039\/D2CS00117A"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-44"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12792"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1523"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"e_1_2_10_46_1","unstructured":"Arvinas WO2018102725A1 2025."},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.4c00379"},{"key":"e_1_2_10_48_1","unstructured":"Arvinas WO2021041348A1 2025."},{"key":"e_1_2_10_49_1","unstructured":"Suzhou Guokuang Pharmaceutical Technology Co. Ltd. CN114085213A 2022."},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29174048"},{"key":"e_1_2_10_51_1","unstructured":"Arvinas Pfizer \u201cA Phase I Open\u2010Label Study to Evaluate the Safety Tolerability and Pharmacokinetics of ARV\u2010471 (PF\u201007850327) a Single Agent in Japanese Participants With ER+\/HER2\u2010Locally Advanced or Metastatic Breast Cancer \u201d2022 accessed Oct 16 2025 https:\/\/cdn.clinicaltrials.gov\/large\u2010docs\/52\/NCT05463952\/Prot_000.pdf."},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2025.114719"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2024.101175"},{"key":"e_1_2_10_54_1","unstructured":"Arvinas \u201cMoving PROTACProtein Degraders From the Laboratory to the Clinic \u201d2019 accessed Oct 20 2025 https:\/\/s3.us\u2010east\u20101.amazonaws.com\/arvinas\u2010assets.investeddigital.com\/scientific\u2010publications\/Targeted\u2010Protein\u2010Degradation\u2010Summit\u2010October\u20102019_FINAL.pdf."},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2021.00061"},{"key":"e_1_2_10_56_1","unstructured":"National Library of Medicine \u201cVepdegestrant \u201d accessed Oct 20 2025 https:\/\/Clinicaltrials.gov\/Expert\u2010Search?term=vepdegestrant."},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.193"},{"key":"e_1_2_10_58_1","unstructured":"Arvinas Pfizer \u201cA Study to Learn about the Study Medicine Called Vepdegestrant (ARV\u2010471 PF\u201007850327) in People with ER+\/HER2\u2010 Advanced Breast Cancer in China.\u201d2023 accessed Oct 20 2025 https:\/\/www.careacross.com\/Clinical\u2010Trials\/Trial\/NCT05732428."},{"key":"e_1_2_10_59_1","unstructured":"Rugbank \u201cVepdegestrant Completed Phase 1 Trials for Healthy Volunteers (HV) Other \u201d accessed Oct 24 2025 https:\/\/go.drugbank.com\/Drugs\/DB19006\/Clinical_trials?conditions=DBCOND0114743&phase=1&purpose=other&status=completed&\u2009Utm."},{"key":"e_1_2_10_60_1","unstructured":"Pfizer \u201cA Study to Understand the Effect of a Study Medicine Called ARV\u2010471 on Rosuvastatin in Healthy Adults \u201d2023 accessed Oct 25 2025.https:\/\/www.pfizer.com\/sites\/default\/files\/plsr\u2010studies\/C4891029%20Plain%20Language%20Study%20Results%20Summary%20%28PLSRS%29%20Phase%201%20PK%20Primary%20Endpoint.pdf 2023 (accessed 25 Oct 2025)."},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70198"},{"key":"e_1_2_10_62_1","unstructured":"Arvinas Pfizer An Interventional Phase 1 Open\u2010Label Fixed\u2010Sequence 2\u2010Period Study To Evsluat the Effect of a Single Oral Dose of ARV\u2010471 (PF\u201007850327) on the Pharmacokinetics of Dabigatran in Healthy Participants 2022. accessed Oct 29 2025 https:\/\/cdn.clinicaltrials.gov\/large\u2010docs\/89\/NCT05673889\/Prot_000.pdf."},{"key":"e_1_2_10_63_1","unstructured":"Pfizer \u201cA Study to Understand the Effect of a Study Medicine Called ARV\u2010471 on Rosuvastatin in Healthy Adults \u201d2023 accessed Nov 2 2025 https:\/\/www.pfizer.com\/sites\/default\/files\/Plsr\u2010Studies\/C4891029%20Plain%20Language%20Study%20Results%20Summary%20%28PLSRS%29%20Phase%201%20PK%20Primary%20Endpoint.pdf."},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70198"},{"key":"e_1_2_10_65_1","unstructured":"Pfizer \u201cA Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults \u201d2024. accessed Nov 2 2025 https:\/\/ichgcp.net\/clinical\u2010trials\u2010registry\/NCT06347861."},{"key":"e_1_2_10_66_1","doi-asserted-by":"crossref","unstructured":"A.Philipovskiy A.Schott J.Cort\u00e9s et al. \u201c256TiP TACTIVE\u2010E: Phase Ib Study of ARV\u2010471 a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader in Combination with Everolimus in ER+\/Human Epidermal Growth Factor Receptor 2 (HER2)\u2010 Advanced Breast Cancer \u201d2023 accessed Nov 2 2025 https:\/\/www.esmoopen.com\/article\/S2059\u20107029(23)00670\u20101\/pdf.","DOI":"10.1016\/j.esmoop.2023.101444"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P4-08-13"},{"key":"e_1_2_10_68_1","unstructured":"Arvinas \u201cOur Clinical Trials Help to Advance the Understanding of Innovative Medicines and Determine whether the New Treatments Being Developed Are Safe and Effective \u201d2025 accessed Nov 2 2025 https:\/\/www.arvinas.com\/Patients\/Clinical\u2010Trials."},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1121"},{"key":"e_1_2_10_70_1","unstructured":"Pfizer \u201cArvinas and Pfizer Announce Initial Phase 1b Data From the TACTIVE\u2010U Sub\u2010Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium \u201d2024. accessed Nov 10 2025 https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/arvinas\u2010and\u2010pfizer\u2010announce\u2010initial\u2010phase\u20101b\u2010data\u2010tactive\u2010u."},{"key":"e_1_2_10_71_1","unstructured":"Pfizer \u201cBreast Cancer \u201d2024. accessed Nov 13 2025 +https:\/\/www.pfizeroncologydevelopment.com\/clinical_trial\/NCT06206837\/molecule\/792+794."},{"key":"e_1_2_10_72_1","doi-asserted-by":"crossref","unstructured":"P. A.Fasching K.Clifton Z.Katashvili et al. \u201c154TiP TACTIVE\u2010N: Open\u2010Label Randomized Noncomparative Neoadjuvant Phase 2 Study of ARV\u2010471 a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader or Anastrozole in Postmenopausal Women with ER+\/Human Epidermal Growth Factor Receptor 2 (HER2)\u2010 Localized Breast Cancer \u201dESMO Open8(2023):101493.","DOI":"10.1016\/j.esmoop.2023.101493"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1122"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1196"},{"key":"e_1_2_10_75_1","unstructured":"Pfizer \u201cArvinas and Pfizer Announce Positive Topline Results From Phase 3 VERITAC\u20102 Clinical Trial \u201d accessed Nov 17 2025 https:\/\/www.pfizer.com\/News\/Press\u2010Release\/Press\u2010Release\u2010Detail\/Arvinas\u2010and\u2010Pfizer\u2010Announce\u2010Positive\u2010Topline\u2010Results\u2010Phase."},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505725"},{"key":"e_1_2_10_77_1","unstructured":"Pfizer \u201cVERITAC\u20103. A Study of Vepdegestrant (ARV\u2010471 PF\u201007850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive Human Epidermal Growth Factor Negative Advanced Breast Cancer \u201d accessed Nov 19 2025 https:\/\/clin.larvol.com\/trial\u2010detail\/NCT05909397."},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.207"},{"key":"e_1_2_10_79_1","unstructured":"Arvinas \u201cArvinas Updates Guidance for First\u2010 and Second\u2010Line Phase 3 Combination Trials with Vepdegestrant Highlights Upcoming Milestones and Provides Corporate Update \u201d 2025 accessed Nov 22 2025 https:\/\/www.globenewswire.com\/News\u2010Release\/2025\/01\/10\/3007559\/0\/en\/Arvinas\u2010Updates\u2010Guidance\u2010for\u2010First\u2010and\u2010Second\u2010Line\u2010Phase\u20103\u2010Combination\u2010Trials\u2010with\u2010Vepdegestrant\u2010Highlights\u2010Upcoming\u2010Milestones\u2010and\u2010Provides\u2010Corporate\u2010Update.html 2025."},{"key":"e_1_2_10_80_1","doi-asserted-by":"crossref","first-page":"LBA1000","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1000","article-title":"Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, Vs Fulvestrant in ER\u2010Positive\/Human Epidermal Growth Factor Receptor 2 (HER2)\u2013negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC\u20102 Study","volume":"43","author":"Hamilton E. P.","year":"2025","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_10_81_1","unstructured":"ArvinasPfizer \u201cArvinas and Pfizer's Vepdegestrant (ARV\u2010471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+\/HER2\u2010 Metastatic Breast Cancer\u201d Can Be Found under \u201c2024 accessed Nov 27 2025 https:\/\/www.pfizer.com\/news\/announcements\/arvinas\u2010and\u2010pfizers\u2010vepdegestrant\u2010arv\u2010471\u2010receives\u2010fda\u2010fast\u2010track\u2010designation."},{"key":"e_1_2_10_82_1","unstructured":"Arvinas \u201cArvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1\u2010Mutated ER+\/HER2\u2010 Advanced or Metastatic Breast Cancer \u201d (2025) accessed Nov 29 2025 https:\/\/ir.arvinas.com\/News\u2010Releases\/News\u2010Release\u2010Details\/Arvinas\u2010Announces\u2010Submission\u2010New\u2010Drug\u2010Application\u2010us\u2010Fda."},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3465"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.04.030"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01137-5"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01462-3"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01104"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107234"},{"key":"e_1_2_10_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02172-4"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00428"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42004-025-01598-9"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomedchemau.2c00037"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.4c00253"}],"container-title":["ChemMedChem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chemistry-europe.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cmdc.202501111","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/chemistry-europe.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cmdc.202501111","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/chemistry-europe.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cmdc.202501111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T07:26:16Z","timestamp":1783841176000},"score":1,"resource":{"primary":{"URL":"https:\/\/chemistry-europe.onlinelibrary.wiley.com\/doi\/10.1002\/cmdc.202501111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":92,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,27]]}},"alternative-id":["10.1002\/cmdc.202501111"],"URL":"https:\/\/doi.org\/10.1002\/cmdc.202501111","archive":["Portico"],"relation":{},"ISSN":["1860-7179","1860-7187"],"issn-type":[{"value":"1860-7179","type":"print"},{"value":"1860-7187","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]},"assertion":[{"value":"2025-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e202501111"}}